You are here

A first-in-class orally bioavailable small molecule dual inhibitor targeting NLRP3 and the dopamine transporter to treat AD

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R44AG069622-01A1
Agency Tracking Number: R44AG069622
Amount: $844,210.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NIA
Solicitation Number: PAS19-316
Solicitation Year: 2019
Award Year: 2021
Award Start Date (Proposal Award Date): 2021-09-30
Award End Date (Contract End Date): 2023-05-31
Small Business Information
Cincinnati, OH 45219-2399
United States
DUNS: 182472162
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (513) 475-6618
Business Contact
Phone: (513) 475-6618
Research Institution

ABSTRACTP2D Bioscience is developing a first-in-class treatment for Alzheimer’s disease (AD). Our
drug is an orally-effective combination that targets both innate immunity and the dopamine
transport (DAT) inhibitor. Recent studies suggest that TNFα and DAT inhibitors are orally
effective treatments for AD in preclinical AD transgenic mouse models.The proposed studies will determine if our compound is an effective treatment for AD using a
three transgenic animal models of AD. The rationale is rigorously evaluation for our lead
compound across different models of AD pathology in this limited direct-to-phase 2 SBIR
application. The proposed specific aims will determine if chronic oral treatment significantly
improves AD symptoms and AD /FTD pathophysiology in these animal models.Aim 1 : Determine the brain and plasma PK profile of our dual acting lead compound to aid
in developing a PKPD correlation.Aim 2: Determine the efficacy of chronic daily oral treatment of our dual acting lead
compound at improving cognitive/behavioral function in three transgenic models of dementia
and their AD-associated pathology

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government